Increased Treatment-Related Toxicity Subsequent to an Anti–PD-1 Agent
Excerpt
The approval of ipilimumab [...]
Share and Cite
Khoja, L.; Butler, M.O.; Chappell, M.A.; Hogg, D.; Joshua, A.M. Increased Treatment-Related Toxicity Subsequent to an Anti–PD-1 Agent. Curr. Oncol. 2015, 22, 320-322. https://doi.org/10.3747/co.22.2418
Khoja L, Butler MO, Chappell MA, Hogg D, Joshua AM. Increased Treatment-Related Toxicity Subsequent to an Anti–PD-1 Agent. Current Oncology. 2015; 22(4):320-322. https://doi.org/10.3747/co.22.2418
Chicago/Turabian StyleKhoja, Leila, Marcus Ortho Butler, Mary Anne Chappell, David Hogg, and Anthony M. Joshua. 2015. "Increased Treatment-Related Toxicity Subsequent to an Anti–PD-1 Agent" Current Oncology 22, no. 4: 320-322. https://doi.org/10.3747/co.22.2418
APA StyleKhoja, L., Butler, M. O., Chappell, M. A., Hogg, D., & Joshua, A. M. (2015). Increased Treatment-Related Toxicity Subsequent to an Anti–PD-1 Agent. Current Oncology, 22(4), 320-322. https://doi.org/10.3747/co.22.2418